Atrás
Rango del Día
$12.51
$13.80
Rango de 52 Semanas
$5.68
$16.74
Volumen
1,207,980
Promedio 50D / 200D
$12.96
/
$9.43
Cierre Anterior
$12.74
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -3.5 | 0.4 |
| P/B | 1.9 | 2.9 |
| ROE % | -44.0 | 3.7 |
| Net Margin % | — | 3.9 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.0 | 0.2 |
Precio Objetivo de Analistas
Hold
$30.43
+137.0%
Low: $26.00
High: $38.00
EPS Futuro
-$3.02
Ingresos Est.
27 M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
-$0.92
-$1.79 – $0.01
|
280 M | 2 |
| FY2029 |
-$2.97
-$5.74 – $0.03
|
70 M | 4 |
| FY2028 |
-$2.52
-$3.24 – -$1.87
|
52 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,582 | $14.47 | $66,302 |
| Feb 24, 2026 |
AHMED NADIM
President and CEO
|
sell | 13,515 | $14.47 | $195,562 |
| Feb 20, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
sell | 4,398 | $13.62 | $59,901 |
| Feb 20, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,982 | $13.62 | $67,855 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 11,742 | $13.62 | $165,366 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
other | 16,000 | $4.30 | — |
| Feb 18, 2026 |
Savill Corrine
Chief Business Officer
|
grant | 175,000 | — | — |
| Feb 18, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
grant | 300,000 | — | — |
| Feb 18, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 206,250 | — | — |
| Feb 18, 2026 |
SUMER JACQUELYN L
Chief Legal Officer
|
grant | 230,000 | — | — |
| Feb 12, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 416 | $12.03 | $5,004 |
| Jan 22, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 4,000 | $12.30 | $49,200 |
| Dec 31, 2025 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 27 | $6.49 | $175 |
| Dec 23, 2025 |
AHMED NADIM
President and CEO
|
sell | 9,922 | $10.01 | $99,319 |
| Dec 19, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 1,345 | $10.01 | $13,463 |
| Dec 18, 2025 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4,632 | $9.67 | $44,791 |
| Dec 18, 2025 |
SUMER JACQUELYN L
Chief Legal Officer
|
sell | 3,480 | $9.67 | $33,652 |
| Dec 18, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2,898 | $9.67 | $28,024 |
| Dec 15, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 995 | $11.90 | $11,841 |
| Dec 12, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2,148 | $12.38 | $26,592 |
Puntos Clave
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -175.80M
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-44.02%
ROIC-44.05%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
0.01
Current Ratio10.25
Interest Coverage0.00
Valoración
P/E Ratio
-3.53
P/B Ratio1.90
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -219.88M |
| ROE | -44.02% | ROA | -49.04% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -175.80M |
| ROIC | -44.05% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 10.25 |
| Interest Coverage | 0.00 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -3.53 | P/B Ratio | 1.90 |
| P/S Ratio | N/A | PEG Ratio | -0.14 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 777.16M | Enterprise Value | 691.51M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 18.94M |
| Net Income | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
| EPS (Diluted) | -3.72 | -3.11 | -3.69 | 2.38 | -1.48 |
| Gross Profit | -311,000.0 | -306,000.0 | 0.0 | 0.0 | 18.94M |
| Operating Income | -241.65M | -196.92M | -191.09M | 144.65M | -67.95M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Total Liabilities | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Shareholders' Equity | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
| Total Debt | 2.68M | 2.15M | 3.59M | 5.19M | 0.0 |
| Cash & Equivalents | 88.33M | 83.01M | 98.43M | 156.15M | 59.77M |
| Current Assets | 386.76M | 414.67M | 480.19M | 474.47M | 296.56M |
| Current Liabilities | 37.74M | 30.65M | 28.14M | 22.50M | 11.75M |